OncoHost to Present Groundbreaking Cancer Research at ASCO 2025 Event
OncoHost's Significant Presence at ASCO 2025
OncoHost, a pioneering technology company located in Binyamina, Israel, and Cary, North Carolina, has revealed that it will present three impactful research abstracts at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Scheduled from May 31 to June 4 in Chicago, Illinois, the presentations underscore OncoHost's commitment to transforming cancer treatment through the lens of precision medicine.
The selected studies will cover various cancer types, including non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and ovarian cancer, showcasing the versatile application of plasma proteomics in personalized treatment strategies. This aligns with OncoHost's focus on advancing host-response biomarker innovation to enhance patient outcomes.
Poster Presentations Overview
1. Longitudinal Plasma Proteomic Analysis as a Monitoring Strategy for NSCLC Patients Treated with Immunotherapy
Presenter: Yehonatan Elon, PhD, CTO at OncoHost
Session Date: May 31, 2025 | Time: 1:30 PM CDT | Location: Hall A – Posters and Exhibits
Abstract Number: 8579 | Poster Board: 59
This study explores how plasma proteomic signatures can dynamically reflect treatment responses in NSCLC patients undergoing immune checkpoint inhibitor therapy. Notably, the research has identified three distinct proteomic patterns: one indicative of drug presence, another showing immune activation, and the last reflecting lung tissue damage. These findings suggest the potential for early identification of non-responders up to 6.6 months before conventional radiologic imaging, which is a significant advancement in patient management. A comparative analysis with circulating tumor DNA (ctDNA) will also be discussed in this presentation.
2. A Plasma Proteomics-Based Model for Predicting Response to Neoadjuvant Chemotherapy in Ovarian Cancer
Presenter: Ofer Sharon, MD, CEO at OncoHost
Session Date: June 2, 2025 | Time: 1:30 PM CDT | Location: Hall A – Posters and Exhibits
Abstract Number: 3056 | Poster Board: 371
This research introduces an innovative computational model utilizing pre-treatment plasma proteomics to forecast chemotherapy responses in high-grade serous ovarian cancer (HGSOC). The findings illustrate the feasibility of employing plasma proteomic data from blood samples obtained before treatment to predict how patients will respond to neoadjuvant chemotherapy, paving the way for more tailored treatment plans.
3. Genomic and Proteomic Predictors of Metastatic Sites in Renal Cell Carcinoma
Presenter: Clara Steiner, MD, Postdoctoral Research Fellow at Dana-Farber Cancer Institute
Session Date: June 2, 2025 | Time: 9:00 AM CDT | Location: Hall A – Posters and Exhibits
Abstract Number: 4538 | Poster Board: 338
This study presents a multi-omics profiling approach for understanding metastatic RCC, identifying genomic alterations and circulating proteins associated with specific metastatic sites such as the lung, bone, and liver. These insights are expected to lead to the creation of non-invasive predictors for metastatic spread, ultimately contributing to the development of more effective site-specific treatment strategies.
Future Prospects in Precision Oncology
Ofer Sharon, CEO of OncoHost, commented on the significance of these presentations, stating, "Our expanding clinical pipeline and participation in ASCO 2025 represent critical milestones in the evolution of precision oncology. By combining advanced proteomic technologies with AI-driven analytics, we continue to demonstrate the versatility of our platform across tumor types and treatment settings—reinforcing our commitment to amplifying oncologists' insights in making more personalized and effective treatment decisions."
About OncoHost
OncoHost is dedicated to reshaping the landscape of precision medicine to enhance patient outcomes. The company's proprietary platform, PROphet®, specializes in plasma-based proteomic pattern analysis. Its flagship offering in NSCLC helps guide treatment decisions for first-line immunotherapy, proving invaluable in clinical settings. Backed by a robust clinical trial network involving over 40 sites and 1,700 patients worldwide, OncoHost is positioned as a leader in precision diagnostics and biomarker innovation.
To learn more, visit OncoHost's website or follow them on LinkedIn, Twitter, Facebook, and YouTube.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.